Prof. Li Xiaoqiu (李小秋) – China's Leading Lymphoma Pathologist at Fudan University Shanghai Cancer Center

About Prof. Li Xiaoqiu

Prof. Li Xiaoqiu (李小秋) is the foremost authority on lymphoma pathology in China, based in the Department of Pathology at Fudan University Shanghai Cancer Center (FUSCC). Nationally recognized for his expertise in difficult and complex lymphoma diagnoses, Prof. Li leads the pathological interpretation of the most challenging cases — those where standard histology is insufficient and molecular marker analysis is essential to arrive at a definitive, treatment-guiding diagnosis.

In lymphoma care, pathology is not a preliminary step — it is the foundation upon which all treatment decisions rest. An incorrect or incomplete pathological diagnosis can lead to the wrong treatment protocol, wasted time, and avoidable toxicity. Prof. Li's role at FUSCC is to ensure that every lymphoma patient receives a diagnosis that is not just histologically accurate but molecularly complete — providing the precise subtype classification that enables oncologists like Prof. Zhao Weili and Prof. Cao Junning to design truly individualized treatment plans.

Clinical & Diagnostic Expertise

• Difficult and complex lymphoma pathology — second-opinion diagnosis for cases where initial pathology is inconclusive, inconsistent with clinical presentation, or requires subspecialty expertise to resolve
• Molecular marker interpretation — comprehensive immunohistochemistry (IHC) panels, FISH for MYC/BCL2/BCL6 rearrangements, in-situ hybridization (ISH), and next-generation sequencing (NGS) for lymphoma subtyping
• DLBCL cell-of-origin classification — GCB vs. ABC/non-GCB subtyping using Hans algorithm and gene expression profiling to guide treatment selection and prognosis
• Double-hit and triple-hit lymphoma identification — FISH-based detection of concurrent MYC and BCL2/BCL6 rearrangements, which define high-grade B-cell lymphoma requiring intensified treatment
• T-cell and NK/T-cell lymphoma pathology — a diagnostically challenging group with high rates of misdiagnosis; Prof. Li's expertise is particularly valuable for these rare subtypes
• Hodgkin lymphoma vs. mediastinal B-cell lymphoma differentiation — critical distinction with major treatment implications, requiring expert pathological interpretation
• Bone marrow biopsy interpretation — assessment of lymphoma involvement, transformation, and treatment response in bone marrow specimens

Why Prof. Li Xiaoqiu?

For international patients who have received a lymphoma diagnosis abroad, one of the most valuable steps before beginning treatment in Shanghai is having their pathology slides reviewed by Prof. Li. Lymphoma pathology is one of the most subspecialized areas in diagnostic medicine, and misclassification rates — even at reputable centers — are not negligible. Studies have shown that expert pathology review changes the diagnosis or significantly refines the subtype classification in 10–20% of lymphoma cases referred to specialized centers.

A revised or more precise diagnosis from Prof. Li can have immediate, concrete consequences for treatment: a patient initially classified as GCB-DLBCL who is reclassified as ABC-DLBCL may benefit from the addition of a BTK inhibitor; a patient with unrecognized double-hit lymphoma requires a fundamentally different induction regimen; a T-cell lymphoma misdiagnosed as B-cell lymphoma would receive entirely the wrong chemotherapy backbone.

Prof. Li works in close collaboration with FUSCC's lymphoma oncology team, ensuring that pathological findings are immediately translated into clinical action. This integrated pathology-oncology workflow — where the pathologist and treating oncologist communicate directly about each case — is one of the hallmarks of FUSCC's lymphoma program and a significant advantage for patients seeking care there.

The Role of Pathology in Lymphoma Treatment

Understanding why expert pathology matters helps international patients appreciate the value of a second pathology opinion before committing to a treatment plan:

• Lymphoma has 60+ subtypes, each with different biology, prognosis, and treatment requirements — accurate subtyping is the prerequisite for appropriate therapy
• IHC panels must include the right markers for the suspected subtype; an incomplete panel can miss critical information (e.g., MYC protein expression, PD-L1 status, EBV-encoded RNA)
• FISH testing for MYC, BCL2, and BCL6 rearrangements is essential for all DLBCL patients — identifying double/triple-hit lymphoma changes the treatment protocol entirely
• NGS (next-generation sequencing) of lymphoma tissue can identify actionable mutations (EZH2, CD79B, MYD88, CARD11) that guide targeted therapy selection
• Tissue adequacy: excisional lymph node biopsy is strongly preferred over core needle biopsy for initial diagnosis; Prof. Li can advise on whether existing biopsy material is sufficient or whether re-biopsy is needed
• Transformation: indolent lymphomas (follicular, CLL/SLL) can transform to aggressive DLBCL — recognizing transformation pathologically is critical as it changes treatment urgency and approach

How to Access Prof. Li's Expertise

International patients can access Prof. Li Xiaoqiu's pathology expertise in two ways:

1. Remote pathology consultation: digital scans of existing pathology slides can be submitted for review before traveling to Shanghai, allowing Prof. Li's team to provide a preliminary assessment and identify whether additional staining or re-biopsy is needed
2. In-person pathology review: physical pathology slides or paraffin-embedded tissue blocks (wax blocks) can be brought to FUSCC for comprehensive re-review and additional molecular testing

CMCS coordinates both pathways for international patients, handling the logistics of slide submission, translation of reports, and communication between Prof. Li's team and the treating oncologist.

How CMCS Can Help

China Medical Concierge Shanghai (CMCS) facilitates access to Prof. Li Xiaoqiu's pathology expertise as part of a comprehensive lymphoma second-opinion or treatment coordination service. Our services include:

• Coordination of remote or in-person pathology slide review with Prof. Li's team
• Logistics support for transporting physical slides or wax blocks to Shanghai
• Translation of pathology reports and molecular testing results
• Integration of pathology findings with oncology consultation at FUSCC
• End-to-end treatment coordination including appointment scheduling, in-hospital accompaniment, and post-treatment follow-up

Contact us to begin your case review:

📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com